tiprankstipranks
Zymeworks Begins Trial for Promising Cancer Therapy
Company Announcements

Zymeworks Begins Trial for Promising Cancer Therapy

Story Highlights
  • Zymeworks starts a Phase 1 trial for ZW171, targeting mesothelin-expressing cancers.
  • The trial evaluates safety and tolerability, with strong preclinical anti-tumor results.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Zymeworks (ZYME) has released an update.

Don't Miss our Black Friday Offers:

Zymeworks has announced the dosing of the first patient in a Phase 1 trial for its investigational therapy ZW171, targeting advanced cancers with mesothelin expression. The trial aims to evaluate the safety and tolerability of ZW171 in ovarian and non-small cell lung cancers, with promising preclinical results showing strong anti-tumor activity.

For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskZymeworks to Showcase Innovations at Investor Conferences
TipRanks Canadian Auto-Generated NewsdeskZymeworks Secures FDA Approval for Ziihera
TheFlyZymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App